Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200–300 nm were synthesized, with a drug encapsulation efficiency of 50–65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment.
Reference:
Semete, B., Kalombo, L., Katata, L., Chelule, P., Booysen, L., Lemmer, Y., Naidoo, S., Ramalapa, B., Hayeshi, R. and Swai, H.S. 2012. Potential of improving the treatment of tuberculosis through nanomedicine. Molecular Crystals and Liquid Crystals, Vol 556(1), pp 317-330
Semete, B., Kalombo, L., Katata, L., Chelule, P., Booysen, L., Lemmer, Y., ... Swai, H. (2012). Potential of improving the treatment of tuberculosis through nanomedicine. http://hdl.handle.net/10204/6396
Semete, B, Lonji Kalombo, L Katata, P Chelule, L Booysen, Yolandy Lemmer, Saloshnee Naidoo, B Ramalapa, R Hayeshi, and HS Swai "Potential of improving the treatment of tuberculosis through nanomedicine." (2012) http://hdl.handle.net/10204/6396
Semete B, Kalombo L, Katata L, Chelule P, Booysen L, Lemmer Y, et al. Potential of improving the treatment of tuberculosis through nanomedicine. 2012; http://hdl.handle.net/10204/6396.
Copyright: 2012 Taylor & Francis. This is the pre print version of the work. The definitive version is published in the journal of Molecular Crystals and Liquid Crystals, Vol 556(1), pp 317-330.
